MedTrace Logo

Autologous Bone Marrow Stem Cells in Ischemic Stroke.

NCT00535197 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2019-07-08

No results posted yet for this study

Summary

The aim of the study is to determine the safety and tolerability of an autologous CD34+ subset bone marrow stem cell infusion into the middle cerebral artery in patients who have suffered acute total or partial anterior circulation syndrome (TACS/PACS).

Conditions

  • Stroke, Acute
  • Infarction, Middle Cerebral Artery

Interventions

BIOLOGICAL

Infusion of autologous CD34+ stem cells into middle cerebral artery

intra-arterial infusion into ipsilateral MCA, via trans-femoral approach

Sponsors & Collaborators

  • Imperial College London

    lead OTHER

Principal Investigators

  • Nagy Habib, Professor · Imperial College London U.K.

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2012-07-31
Completion
2012-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00535197 on ClinicalTrials.gov